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Abstract
Background: In critically ill patients the incidence of invasive fungal infections caused by Candida spp. has
increased remarkably. Echinocandins are recommended as initial treatment for invasive fungal infections. The safety
and efficacy of micafungin compared to caspofungin is similar, but no comparison is made between anidulafungin
and micafungin concerning safety and efficacy. We therefore performed a retrospective study to assess these
aspects in critically ill patients with invasive candidiasis.
Methods: All patients in the intensive care unit (ICU) with invasive candidiasis, who were only treated with
anidulafungin or micafungin, between January 2012 and December 2014 were retrospectively included. Baseline
demographic characteristics, infection characteristics and patient courses were assessed.
Results: A total of 63 patients received either anidulafungin (n = 30) or micafungin (n = 33) at the discretion of the
attending intensivist. Baseline characteristics were comparable between the two groups, suggesting similar risk for
developing invasive candidiasis. Patients with invasive candidiasis and liver failure were more often treated with
anidulafungin than micafungin. Response rates were similar for both groups. No difference was observed in 28-day
mortality, but 90-day mortality was higher in patients on anidulafungin. Multivariable cox regression analysis
showed that age and serum bilirubin were the best parameters for the prediction of 90-day mortality, whereas
APACHE II, Candida score and antifungal therapy did not contribute (P > 0.05). None of the patients developed
impaired liver function related to antifungal use and no differences were seen in prothrombin time, serum
transaminases and bilirubin levels between the groups, after exclusion of patients with liver injury or failure.
Conclusion: Micafungin can be safely and effectively used in critically ill patients with invasive candidiasis. The
observed increased 90-day mortality with anidulafungin can be explained by intensivists unnecessarily avoiding
micafungin in patients with liver injury and failure.
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Background
The incidence of invasive fungal infections caused by
Candida spp. is increasing in critically ill patients [1, 2].
The latter is associated with prolonged duration of
hospitalization and higher mortality rates [3–5]. The
mortality of invasive candidiasis is directly correlated
with a delay in starting antifungal therapy and therefore
early treatment with an appropriate antifungal drug is
mandatory [6, 7].
A relatively novel class of antifungal agents are echino-
candins which have activity against a broad spectrum of
Candida spp., including C. glabrata and C. krusei, against
which fluconazole has less activity [8]. Echinocandins are
recommended as initial treatment for invasive candidiasis
in patients with moderate to severe illness, keeping
fluconazole reserved for less critically ill patients [9]. The
recommendation are based on prospective randomized
clinical trials which demonstrated that all three echino-
candins are at least as effective as fluconazole for the
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treatment of invasive candidiasis [10–15]. The antifungal
activity, pharmacokinetics and toxicity profile of each
echinocandin is slightly different, but the relevance of this
finding remains unclear [16]. Both caspofungin and
micafungin undergo hepatic metabolism, in contrast to
anidulafungin, which undergoes spontaneous degradation
[17]. Concerns about possible hepatotoxicity of micafun-
gin have been raised which may affect its use in daily prac-
tice [2]. Two randomized controlled trials [16, 18] and
one retrospective observational trial [19], compared the
safety and efficacy of micafungin versus caspofungin in
the treatment of invasive candidiasis, showing similar
results in the safety and efficacy of micafungin compared
with caspofungin. One systematic review including 8,000
patients [20] and one observational cohort study with
8,696 patients [21], evaluated the safety of micafungin
versus other echinocandins, showing no increased risk of
hepatic injury by micafungin. Both studies only evaluated
the safety concerning hepatotoxicity of antifungal medica-
tion in mostly non-ICU patients, but did not evaluate
mortality or efficacy.
As far as we are aware there are no studies comparing
the efficacy and safety of micafungin versus anidulafun-
gin in critically ill patients with invasive candidiasis. We
performed a retrospective study to compare the safety
and efficacy of micafungin versus anidulafungin in critic-
ally ill patients with invasive candidiasis.
Methods
Patients
We retrospectively gathered data from the patients’
medical records using a predefined checklist. Between
January 1, 2012, and January 1, 2015, all patients over
the age of 18 with invasive candidiasis and who only
received anidulafungin or micafungin as systemic
antifungal treatment in the Intensive Care Unit (ICU) of
the Erasmus University Medical Center Rotterdam, were
considered for participation. Candidemia was defined as
at least one positive blood culture for Candida spp.
drawn from a peripheral vein. Invasive candidiasis was
defined as a positive culture with Candida spp. obtained
from a normally sterile site, such as pleural or peritoneal
fluid, in the context of pleural exsudate/empyema, and
secondary or tertiary peritonitis following a ruptured
viscus and surgery, respectively [22]. In addition,
patients needed to have one or more of the following
signs and symptoms of infection: fever or hypothermia;
hypotension; localized signs and symptoms of inflamma-
tion; or radiological findings of invasive candidiasis.
Between January 2012 and December 2014 there were
124 patients diagnosed with invasive candidiasis of
whom 20 received caspofungin, 38 stepped-down to
fluconazole and 3 received both antifungals. In total
there were 63 patients with invasive Candida spp.
infection who only received anidulafungin or micafun-
gin. The Dutch law states that informed consent is not
required in case of retrospective analysis in which data
collected during routine clinical care were used and
anonymously analyzed.
Clinical protocol
Patients were taken care of by attending intensivists
according to national and local guidelines. In our center
selective decontamination of the digestive tract (SDD) is
routinely used for patients with an expected duration of
mechanical ventilation for more than 48 h. This involves
administration of an oral paste and of a suspension via
the nasogastric tube, containing the non-absorbable
antibiotics tobramycin, amphotericin-B and colistin.
Patients also received cefotaxime intravenously at 4
times 1 g a day for a three-day period. Inventory cultures
are taken of the throat, tracheal aspirates, and rectum as
part of this protocol on admission. To monitor the effect
of SDD treatment, surveillance cultures (from throat,
tracheal aspirates, and rectum) were routinely performed
three times per week. All SDD cultures were screened
for the presence of Gram-negative rods, and yeast that
were identified to the species level (see below). In case a
patient is suspected for having an infection, additional
cultures (besides the routinely SDD cultures) can be
taken from the possible source of infection, which
includes the use of blood cultures. All materials obtained
from a normally sterile site were cultured onto relevant
agar plates for the detection of both bacteria and yeast.
Blood culture bottles, specific for the recovery of yeast
(BACTEC Mycosis IC/F), that became positive were sub-
cultured onto chocolate agar, Sabouraud agar, and
CHROMagarTM to ensure purity or mixed infection and
differentiation of yeast, and incubated at 35 °C. Auxaco-
lor (Sanofi Diagnostics Pasteur) or MALDI-TOF was
used to identify the species level of a Candida colony as
soon as visible growth from a normally sterile site was
observed. Susceptibility testing of isolates obtained from
normally sterile sites was performed using a CLSI broth
microdilution method (Sensititre®, Thermoscientific,
USA) and results for azoles, amphotericin B and caspo-
fungin, were reported according to revised species-
specific CLSI clinical breakpoints. For fluconazole, C.
albicans was considered susceptible if the minimum
inhibitory concentration (MIC) was ≤2 mg/L, and
reduced susceptibility was defined as a MIC of ≥4 mg/L
[23], after 24–48 h of growth. The decision to start an
echinocandin was taken by the attending intensivist in
collaboration with infectious disease specialist. The initi-
ation of antifungal therapy was based on clinical signs
(i.e. fever, hypothermia, hypotension, leukocytosis or
leukopenia), risk factors for invasive candidiasis, culture
results, radiological findings of invasive candidiasis, and
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according to published criteria [9]. Caspofungin was
introduced in 2001, followed by anidulafungin and mica-
fungin respectively. In case of severe liver injury and
liver failure, which was defined as the presence of clin-
ical signs and symptoms of an abnormal liver function
(increased liver enzymes, hyperbilirubinemia, coagulopa-
thy and encephalopathy), intensivists prefer anidulafun-
gin over micafungin. In all other instances, the choice
between anidulafungin or micafungin was at the discre-
tion of the attending intensivist. For anidulafungin
patients received an intravenous daily dose of 100 mg
after an initial single loading dose of 200 mg. Micafungin
was administered at a dose of 100 mg intravenous once
daily without a loading dose. No dose adjustment was
needed for body weight or impaired renal or hepatic
function. Drainage of suspected pus collections as well
as removal of IV catheters suspected to be the origin of
infection was routinely done. The duration of the anti-
fungal therapy was decided in close collaboration with
the infectious diseases physician, based on Dutch inva-
sive fungal infection guidelines which take several factors
into account, such as duration of positive cultures, the
certainty of good drainage and clinical improvement
(absence of fever for >24 h, haemodynamic stability, and
neutropenia) [9, 24, 25].
Study protocol and data collection
Demographic data and clinical date were recorded on
admission, including severity of illness scores, risk
factors for invasive Candida spp. infection (neutro-
penia, recent surgery, diabetes mellitus, cancer, mech-
anical ventilation, renal replacement therapy, total
parenteral nutrition, transplant and central venous
catheters), the duration of ICU stay, and mortality at
day 28 and 90 after start of antifungal therapy.
Patients were checked for abnormal liver function
during antifungal therapy, serum aspartate transamin-
ase (AST) and serum alanine transferase (ALT) were
recorded at start and stop of echinocandin treatment.
Serum bilirubin, prothrombin time (PT), AST, and
ALT peak values were recorded daily during echino-
candin treatment. At the start of echinocandin treat-
ment a Candida score was calculated for each patient
to help, when >3, establishing the risk for invasive
candidiasis vs colonization [26]. The primary site of
infection and the obtained culture results were
recorded. A global response at the end of treatment
was defined as both clinical success (cure – resolution
of signs and symptoms of Candida spp. infection, or
improvement – incomplete resolution of signs and
symptoms of Candida spp. infection) and microbio-
logical success (2 negative follow-up cultures for
Candida spp., or presumed eradication when the
follow-up culture was not available and clinical
response was defined as cure or improvement at the
end of treatment). The duration of Candida spp.
infection was defined as the period between the first
positive culture and the first negative culture or ICU
death or discharge. Duration of treatment was defined
as the period between initiation and stop of antifungal
therapy or ICU death or discharge.
Statistical analysis
Continuous variables were presented with median and
interquartile range because of the not normal distribu-
tion (Kolmogorov-Smirnov test, P < 0.05). Continuous
data were examined with The Mann–Whitney U test
and categorical data with the Fisher exact test. The
Kaplan-Meier estimation of survival curves (com-
pared by log rank tests) and multivariable cox
regression were used for survival analysis. All
reported P values are two-tailored. Statistical signifi-
cance was set at P < 0.05.
Results
Sixty-three patients with invasive candidiasis received
either anidulafungin (n = 30) or micafungin (n = 33).
Patients using anidulafungin were more often on renal
replacement therapy (Table 1).
Infection and treatment characteristics
Of the 63 patients, 22 patients had candidemia, 37
patients had abdominal and 4 patients had pleural infec-
tion (Table 2). The average Candida score was 3 for
both groups. Anidulafungin was initiated at median day
3 and micafungin was initiated at median day 2 after
ICU admission. There were no echinocandin-resistant
strains. Four C. albicans isolates were considered less
sensible to fluconazole with an average clinical break-
point of 100 mg/L. There was no difference in the
duration of treatment and infection, and response rates,
even when corrected for liver failure. Both groups had a
similar duration of ICU stay. No difference was observed
in 28-day mortality, but 90-day mortality was higher in
patients on anidulafungin (Table 2 and Fig. 1). Multivari-
able Cox regression analysis showed that age (hazard
ratio 1.13, 95 % confidence interval 1.02–1.23, P = 0.02)
and serum bilirubin (hazard ratio 1.06, 95 % confidence
interval 1.01–1.12, P = 0.03) were the best parameters
for the prediction of 90-day mortality, whereas APACHE
II, Candida score and antifungal therapy did not con-
tribute (P > 0.05).
Liver enzymes and function
Patients with invasive candidiasis and liver failure
were more often treated with anidulafungin than
micafungin. None of the patients in this study devel-
oped liver failure or elevated liver enzymes requiring
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cessation of treatment related to the use of an echinocan-
din. PT, AST, ALT and bilirubin levels tended to be higher
in patients treated with anidulafungin. When excluding
liver failure, no differences were seen in PT, AST, ALT and
bilirubin levels between the groups (Table 3).
Costs
Table 4 describes the involved costs for both treatment
strategies. The total treatment costs per patient seemed
to be higher for micafungin, because of the longer treat-
ment period. However, the treatment costs per patient
per day were lower for micafungin.
Discussion
This study suggests that in critically ill patients with
candidemia or invasive candidiasis, the safety and effi-
cacy of the treatment with micafungin was similar to
that of anidulafungin. No differences were seen in
response rates, liver function and enzymes, and mortality.
Treatment with micafungin seems to be less expensive
then that with anidulafungin.
Echinocandins inhibit synthesis of the β-(1–3)-D-
glucan compound of the fungal cell wall and are
considered as safe drugs [2, 17]. The overall efficacy
between the three echinocandins is comparable, show-
ing only little difference [27]. Nevertheless, the EMA
still recommend to only use micafungin in case other
antifungals are not appropriate, as rat experiments
suggested a potential risk for the development of liver
tumors [27]. However, these results were obtained
from studies using high dosages for prolonged time in
male animals, similar effects were not reported by
other studies on humans or animals [17]. Both caspo-
fungin and micafungin undergo hepatic metaboliza-
tion, in contrast to anidulafungin, which undergoes
spontaneous degradation [17]. Transient elevation of
liver enzymes occurs in 2 to 15 % of patients treated
Table 2 Infection and treatment characteristics
Anidulafungin Micafungin P
(n = 30) (n = 33)
Candida score at start 3 (2) 3 (3) 0.71
Source of isolatesa 0.25
Blood 10 (33) 12 (36)
Intra-abdominal fluid 17 (57) 20 (63)
Pleural fluid 3 (10) 1 (3)
Candida spp.a 0.46
Candida albicans 8 (27) 3 (9)
Candida dublienis 0 (0) 2 (6)
Candida glabrata 17 (57) 21 (66)
Candida krusei 3 (10) 3 (10)
Candida parapsilosis 1 (3) 2 (6)
Candida tropicalis 1 (3) 2 (6)
Global responsea 21 (67) 23 (70) 0.80
Clinical responsea 24 (80) 28 (85) 0.62
Microbial responsea 21 (70) 24 (73) 0.81
Gaining negative culturesa 18 (60) 20 (60) 0.96
Duration of infection (days) 3 (5) 3 (5) 0.80
Duration of treatment (days) 12 (8) 14 (9) 0.40
Length of ICU stay (days) 13 (15) 14 (21) 0.64
Mortality day 28 after starta 20 (67) 18 (55) 0.33
Mortality day 90 after starta 26 (87) 21 (64) 0.04
Numbers (percentage) aor median (interquartile range), where appropriate
Abbreviations: ICU intensive care unit
Table 1 Baseline demographic and clinical characteristics
Anidulafungin Micafungin P
(n = 30) (n = 33)
On admission
Age (years) 59 (20) 62 (20) 0.36
Gender (male)a 19 (63) 26 (79) 0.18
APACHE II score 26 (10) 23 (8) 0.13
SOFA score 10 (9) 9 (3) 0.63
Reasons of ICU admissiona 0.14
Suspected sepsis 9 (30) 11 (33)
Respiratory failure 2 (7) 6 (19)
Renal failure 1 (3) 0 (0)
Liver failure 4 (13) 0 (0)
CPR 2 (7) 2 (6)
Shock 5 (17) 3 (10)
Postoperative 7 (23) 11 (34)
At start of echinocandin
Risk factors for invasive candidiasisa
Neutropenia 3 (10) 2 (6) 0.57
Broad spectrum antibiotics 18 (60) 15 (45) 0.25
Immunosuppression 4 (13) 3 (9) 0.60
Steroids 16 (53) 12 (36) 0.18
TPN 4 (13) 11 (33) 0.07
Recent Surgery 8 (27) 15 (45) 0.13
DM II 11 (37) 7 (21) 0.18
Malignancy 5 (17) 11 (33) 0.13
Transplant 5 (17) 4 (12) 0.61
CVVH 19 (63) 7 (21) 0.001
CVC 29 (97) 29 (88) 0.20
Mechanical ventilation 27 (90) 32 (97) 0.26
Duration between admission and
start echinocandin (days)
3 (4) 2 (2) 0.17
Numbers (percentage) aor median (interquartile range), where appropriate
List of abbreviations: APACHE II Acute Physiology and Chronic Health
Evaluation II, CPR cardiac pulmonary resuscitation, CVVH continuous
venovenous haemofiltration, CVC central venous catheter, DM II diabetes
mellitus type II, ICU intensive care unit, TPN total parenteral nutrition
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with an echinocandin [28]. In this study we found an
elevation in serum AST of 38 % and 35 %, and an
elevation in serum ALT of 33 % and 29 %, in patients
treated with anidulafungin or micafungin, respectively.
The observed incidence of elevated liver enzymes in
this study is much higher, but equal between both
groups of echinocandins, but we only looked at
elevated liver enzymes in general and not specifically
caused by the echinocandins. Abnormal liver function
tests can be found in up to 61 % of critically ill
patients, as caused by sepsis, drugs or ischemia [29].
Our results suggest that micafungin is as safe as
anidulafungin concerning hepatotoxicity. The results
are in line with two previous studies, which both
concluded that anidulafungin and micafungin had a
low risk of elevated liver enzyme levels not requiring
the cessation of treatment [20, 21]. Both studies only
evaluated the safety concerning hepatotoxicity of anti-
fungal medication in mostly non-ICU patients, but
did not evaluate mortality or efficacy, as we did.
Therefore, this study adds important information
about the safety and efficacy of micafungin compared
with anidulafungin in critically ill patients. At day 28
the overall mortality was 60 % which is comparable
to the mortality described in other studies [30, 31].
The data suggest that higher 90-day mortality with
anidulafungin than micafungin reflects more severe
underlying liver disease rather than effect of treat-
ment itself.
The type and duration of treatment of invasive candid-
iasis depends on culture results and sensitivity testing,
the extent of organ involvement and patients’ clinical
condition [9, 24]. In patients with invasive fungal infec-
tions the recommended length of therapy is 14 days after
the first negative blood culture [9, 24], which is in line
with the observed median length of treatment of 12–14
days in this study. The overall response rates in this
study are comparable to those found in other performed
studies [11, 32]. The overall response rate of micafungin
is comparable to that of anidulafungin. Our retrospective
data, concerning the safety and efficacy of micafungin
are in line with a recent performed study, which
evaluated the safety and efficacy of micafungin mono-
therapy in critically ill patients with cancer and invasive
candidiasis [32]. However, the study did not make a
comparison with anidulafungin, as we did. The pharma-
cokinetics of micafungin are very well defined in non-
critically ill patients and seems to be similar in critically
ill patients [33]. In critically ill patients micafungin
reaches a steady state by day 3, without the need for a
loading dose, in contrast to caspofungin and anidulafun-
gin [9, 24, 25, 33]. Dose adaptations are not required for
body weight and in patients with renal or hepatic
impairment and renal replacement therapy [33]. The
Fig. 1 Kaplan-Meier survival curve up to day 90 after initiation of an echinocandin, P = 0.04 (log rank test). Numbers at risk, micafungin group: 33,
19, 14, 13, 12. Numbers at risk, anidulafungin group: 30, 12, 8, 5, 4
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involved costs per patient per day of treatment with
micafungin seems to be a bit lower compared with
anidulafungin.
One of the limitations of this study is the relatively
small number of patients included, so that results should
be regarded as preliminary. This study enrolled 63
patients with invasive candidiasis caused by Candida
spp. in a four year period in a tertiary care ICU with
2,000 admissions per year. Hence, the reported incidence
of invasive candidiasis in a large review was 5 to 10 cases
per 1,000 ICU admission, which is comparable with our
reported incidence of 6 per 1,000 ICU admissions [34].
Second, because of the retrospective design we cannot
exclude that the use of either agent may have been
subject to bias.
Conclusion
In conclusion, our results suggest that micafungin can
be safely and effectively used in critically ill patients
with candidemia and invasive candidiasis.
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Table 3 Liver enzymes and function
A Anidulafungin Micafungin P
(n = 30) (n = 33)
Liver failurea 9 (30) 2 (6) 0.01
Increased serum AST (U/L)
after starta
13 (43) 12 (36) 0.58
Increased serum ALT (U/L)
after starta
13 (43) 10 (30) 0.29
Serum AST (U/L) at start 95 (282) 55 (76) 0.09
Serum ALT (U/L) at start 56 (125) 39 (59) 0.13
Serum AST (U/L) at stop 115 (1011) 52 (108) 0.17
Serum ALT (U/L) at stop 75 (312) 45 (68) 0.14
Serum AST (U/L) peak 285 (228) 116 (181) 0.11
Serum ALT (U/L) peak 150 (404) 70 (126) 0.15
Serum bilirubin (μmol/L) peak 71 (192) 15 (29) 0.05
Prothrombin Time (sec) peak 18.3 (15.4) 17.8 (8.0) 0.27
B Anidulafungin Micafungin P
(n = 21) (n = 31)
Increased serum AST (U/L)
after starta
8 (38) 11 (35) 0.85
Increased serum ALT (U/L)
after starta
7 (33) 9 (29) 0.74
Serum AST (U/L) at start 61 (98) 55 (73) 0.82
Serum ALT (U/L) at start 43 (75) 39 (54) 0.89
Serum AST (U/L) at stop 44 (141) 49 (79) 0.98
Serum ALT (U/L) at stop 41 (83) 45 (54) 0.99
Serum AST (U/L) peak 129 (267) 113 (158) 0.88
Serum ALT (U/L) peak 69 (209) 61 (119) 0.95
Serum bilirubin (μmol/L) peak 20 (105) 14 (27) 0.74
Prothrombin Time (sec) peak 16.6 (7.5) 17.8 (5.3) 0.68
Numbers (percentage) aor median (interquartile range). Liver enzymes and
function in all patients who were treated with anidulafungin and micafungin
(A) and in patients without liver failure (B)
Abbreviations: ALT alanine transaminase, AST aspartate transaminase
Table 4 Treatment costs
Anidulafungin Micafungin
(n = 30) (n = 33)
Total treatment days 354 429
Total drug dose (mg) 41.600 42.900
Total drug costs (€) 183,805.44 209,553.63
Drug costs per patient (€) 6,126.84 6,350.11
Drug costs p.p.p.d. (€) 519.22 488.47
Micafungin costs € 460.82 (excluding VAT) per 100 mg ampoule, € 488.47
(including 6 % VAT)
Anidulafungin costs € 416.83 (excluding VAT) per 100 mg ampoule, € 441.84
(including 6 % VAT)
Abbreviations: p.p.p.d. per patient per day
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